61 – 70 of 120
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Effects of a culturally adapted lifestyle intervention on cardio-metabolic outcomes : a randomized controlled trial in Iraqi immigrants to Sweden at high risk for Type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome
(
- Contribution to journal › Article
-
Mark
Comparison of eye movement desensitization and reprocessing therapy, cognitive behavioral writing therapy, and wait-list in pediatric posttraumatic stress disorder following single-incident trauma: a multicenter randomized clinical trial
(
- Contribution to journal › Article
- 2016
-
Mark
Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke
(
- Contribution to journal › Article
-
Mark
Global binding pattern of the Wilms' tumor gene 1 (WT1) +17AA -KTS isoform in leukemic cells
2016) American Association for Cancer Research (AACR) 107th Annual Meeting 2016 In Cancer Research 76(14 Suppl.).(
- Contribution to journal › Published meeting abstract
-
Mark
Outpatient comprehensive geriatric assessment: Effects on frailty
(
- Contribution to journal › Published meeting abstract
-
Mark
Long-Term Evaluation of the Ambulatory Geriatric Assessment : A Frailty Intervention Trial (AGe-FIT): Clinical Outcomes and Total Costs After 36 Months
(
- Contribution to journal › Article
-
Mark
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures
(
- Contribution to journal › Article
-
Mark
Genetic Determinants of Dyslipidemia
2016)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
(
- Contribution to journal › Article